{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:31Z","timestamp":1790916811243,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":153,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101276","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:52:35Z","timestamp":1781070755000},"page":"101276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness of pegylated liposomal doxorubicin (Caelyx\u00ae) monotherapy in patients with metastatic HER2-low breast cancer: a monocentric retrospective study"],"prefix":"10.1016","volume":"48","author":[{"given":"Philippe","family":"Boudier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-9635","authenticated-orcid":false,"given":"Herv\u00e9","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Pflumio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathie","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Velten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101276_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101276_bib0002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0004","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0005","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Herceptin Adjuvant (HERA) Trial Study Team, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101276_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101276_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101276_bib0008","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2026.101276_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-021-01492-x","article-title":"Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry","volume":"23","author":"Gampenrieder","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101276_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2026.101276_bib0013","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/cancers15010126","article-title":"Current biological, pathological and clinical landscape of HER2-low breast cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101276_bib0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0016","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","volume":"28","author":"Gianni","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0017","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group","volume":"11","author":"Seshadri","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101276_bib0019","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database","volume":"9","author":"Peiffer","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"DESTINY-Breast04 trial investigators, Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101276_bib0021","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","article-title":"erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer","volume":"90","author":"Paik","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101276_bib0022","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jnci\/90.18.1346","article-title":"erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer","volume":"90","author":"Thor","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101276_bib0023","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B","article-title":"Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer","volume":"26","author":"J\u00e4rvinen","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0024","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.2007.15.4716","article-title":"HER-2 and topoisomerase II as predictors of response to chemotherapy","volume":"26","author":"Pritchard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(11)70231-5","article-title":"HER2\/TOP2A Meta-analysis Study Group, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","volume":"12","author":"Di Leo","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0026","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1200\/JCO.2013.54.7869","article-title":"Predicting anthracycline benefit: TOP2A and CEP17-not only but also","volume":"33","author":"Bartlett","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0027","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101276_bib0028","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"CAELYX Breast Cancer Study Group, reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101276_bib0029","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","article-title":"The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial","volume":"94","author":"Al-Batran","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clbc.2016.06.001","article-title":"Biweekly pegylated liposomal doxorubicin (Caelyx) in heavily pretreated metastatic breast cancer: a phase 2 study","volume":"16","author":"Jehn","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0031","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000080363","article-title":"Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure","volume":"27","author":"Mlineritsch","year":"2004","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101276_bib0032","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus Vinorelbine or Mitomycin C plus Vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101276_bib0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-022-06844-5","article-title":"A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer","volume":"198","author":"Bischoff","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101276_bib0034","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101276_bib0035","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2026.101276_bib0036","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","article-title":"The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial","volume":"94","author":"Al-Batran","year":"2006","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:56:46Z","timestamp":1790913406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"alternative-id":["S2468294226001875"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101276","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of pegylated liposomal doxorubicin (Caelyx\u00ae) monotherapy in patients with metastatic HER2-low breast cancer: a monocentric retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101276"}}